Introduction
============

Normal pregnancy is characterized by profound changes in almost every organ system to accommodate the demands of the fetoplacental unit. Normal pregnancy is also characterized by increased renal perfusion, i.e. a rise in the glomerular filtration rate (GFR) and renal blood flow. The increase in GFR can be demonstrated within one month of conception and reaches a peak approximately 40% to 50% above baseline levels by the end of the first trimester \[[@R1]\]. Moreover, renal blood flow increases by 80% above non-pregnant values. The glomerular hyperfiltration results in a normal reduction in the plasma creatinine concentration to about 0.4 mg/dl to 0.5 mg/dl (35 mmol/l to 44 mmol/l); thus, a "normal" level of 0.8 mg/dl (70 mmol/l) during pregnancy represent a mild decline in renal function, possibly from some underlying renal disease. It is well known that serum creatinine is an imperfect marker to measure GFR. There has been interest in exploring other biomarkers for estimating renal function. The most promising agent seems to be cystatin C \[[@R2]\]. The value of neutrophil gelatinase-associated lipocalin (NGAL) was highlighted as a novel biomarker of kidney function \[[@R3]\]. Because of its small molecular size (25 kDa) and resistance to degradation, NGAL is readily excreted and detected in urine as cystatin C. Taking all these data into consideration, the aim of the study was to assess whether NGAL could reflect kidney function in pregnant healthy women. We also assessed correlations between NGAL, cystatin C, creatinine and estimated GFR (eGFR) using 3 formulae.

Material and methods
====================

We assessed kidney function in 130 healthy pregnant women (*n* = 46, 1^st^ trimester, *n* = 21, 2^nd^ trimester and *n* = 63, 3^rd^ trimester) and 30 healthy female volunteers (to establish the normal range for NGAL). The inclusion criteria were: physiological, uncomplicated pregnancy, no inflammation/infection, no prior kidney disease. The exclusion criteria were: complications of pregnancy (imminent abortion, premature delivery, bleeding, cramps requiring drugs/hospitalizations), history of kidney diseases, anaemia, infection, comorbidities (diabetes, hypertension, etc). Since NGAL is affected by kidney function \[[@R3]\] we included only females with normal kidney function (creatinine less than 1.2 mg/dl, eGFR in the normal range of 90-120 ml/min). All the subjects were informed about the aim of the study and gave their consent. The study was approved by the local Medical University Ethic Committee. Healthy volunteers were recruited mainly from the medical staff and their friends and families. We assessed kidney function according to the simplified MDRD equation (eGFR = 186.3 × serum creatinine (mg/dl)^--1.14^ × age^--0.203^ × 0.742 if female × 1.21 if Afro-American) and Cockcroft-Gault formula (creatinine clearance = \[140-age\] × body weight/serum creatinine × 72 if female × 0.85) and new CKD-EPI formula \[[@R4]\].

Serum NGAL (ANTIBODYSHOP, Gentofte, Denmark), cystatin C (Dade Behring, Marburg, Germany), IL-6 (R&D, Abingdon, UK), hs-CRP (American Diagnostica, Greenwich, CT, USA) were assayed using commercially available kits. Complete blood count, serum iron, total iron-binding capacity (TIBC), ferritin, and creatinine were assayed by means of standard laboratory methods in the central laboratory. All tests were performed according to manufacturers' instructions by the same person. ANOVA or Kruskal-Wallis ANOVA was used in statistical analysis.

Results
=======

All the data are presented in Table [I](#TI){ref-type="table"}. We observed a statistically significant fall in serum creatinine in the 2^nd^ trimester together with a rise in eGFR, when compared with the 1st trimester. Serum cystatin C rose steadily during the pregnancy, whereas NGAL rose in the 2^nd^ trimester, then decreased in the 3^rd^ trimester. In pregnant females, eGFR (all formulae) was significantly higher in the 2^nd^ trimester when compared to the 1^st^ and 3^rd^ trimesters. NGAL correlated with serum cystatin C (*r* = 0.25, *p* \< 0.05), number of pregnancies (*r* = 0.25, *p* \< 0.05), white blood cell count (*r* = 0.29, *p* \< 0.01), neutrophil count (*r* = 0.35, *p* \< 0.01), TIBC (*r* = --0.21, *p* \< 0.05), ferritin (*r* = 0.36, *p* \< 0.01), and IL-6 (*r* = 0.23, *p* \< 0.05), and tended to correlate with eGFR. Serum cystatin C correlated with eGFR by MDRD (*r* = --0.19, *p* \< 0.05), white blood cell count (*r* = 0.22, *p* \< 0.05), neutrophil count (*r* = 0.33, *p* \< 0.001), TIBC (*r* = 0.43, *p* \< 0.001), IL-6 (*r* = 0.30, *p* \< 0.01), hs-CRP (*r* = 0.20, *p* \< 0.05), number of pregnancies (*r* = 0.45, *p* \< 0.001), and NGAL (*r* = 0.25, *p* \< 0.05) (Figure [1](#F1){ref-type="fig"}), and tended to correlate with creatinine. In multiple regression analysis the associate of serum NGAL was cystatin C (beta value 0.84, *p* = 0.008), multiple adjusted *r* ^2^ = 0.70, *F* = 2.99, *p* \< 0.034, SE = 5.54.

In multiple regression analysis, the associates of cystatin C were NGAL (beta value --0.42, *p* = 0.00016), neutrophil count (beta value 0.58, *p* = 0.02), and IL-6 (beta value 0.34, *p* = 0.0019), explaining 63% of the variations of cystatin C concentration (*F* = 13.15, *p* \< 0.000001, SE = 0.23).

In healthy females, serum NGAL correlated with age (*r* = 0.35, *p* \< 0.05), serum creatinine (*r* = 0.47, *p* \< 0.01), eGFR (*r* = --0.59, *p* \< 0.001), leukocyte count (*r* = 0.36, *p* \< 0.05), and cystatin C (*r* = 0.44, *p* \< 0.01).

Discussion
==========

We have shown in our study that in pregnant healthy females, NGAL did not reflect changes in GFR during pregnancy. The only predictor of NGAL concentration was cystatin C. The high rate of filtration in pregnancy persists until term \[[@R1]\]. Serum creatinine is an imperfect marker to measure GFR because the total amount of creatinine in plasma water, and therefore the plasma concentration, is dependent on muscle mass, as well as some lesser variables. When any single measurement of plasma creatinine is compared to the whole range of normal values, a marked reduction in renal function (40% to 50%) is necessary before a rise in plasma creatinine into the abnormal range is observed. Efforts have been made to measure GFR from a single measurement of creatinine using various formulae to account for dependent variables. However, accuracy has been poor when the creatinine value has been in the normal or near normal range. In recent years, there has been interest in exploring other biomarkers for estimating renal function. Inspection of reports where cystatin C was compared to gold standard markers has resulted in mixed reviews concerning its potential usefulness \[[@R5]\]. In addition, cystatin is affected by hyper- and hypothyroidism, and, as we also observed in our study, has been correlated with markers of inflammation (C-reactive protein) \[[@R6]\]. Although cystatin C appears to be more accurate for the assessment of GFR than serum creatinine in certain populations, whether or not measurement of cystatin C levels will improve patient care is unknown at present.

In contrast to the expected decrease in cystatin C during the first and second trimesters, as observed in the levels of plasma creatinine, the serum levels of cystatin C increased in pregnancy \[[@R7]\]. Cysteine-proteases are important in pregnancy for implantation and trophoblast invasion of the placenta. Cystatin C is the strongest extracellular inhibitor of cysteine proteases and was originally cloned from placental cDNA \[[@R8]\]. A study that analysed expression of cystatin at the mRNA and protein level in human placental tissue from normal and pre-eclamptic pregnancies showed that cystatin C was synthesized by the placenta and secreted by trophoblast cells into the fetal and maternal circulation \[[@R9]\]. Cystatin C played a role in placentation, and placental production accounted for the increase in cystatin C in normal pregnancy and the further rise in pre-eclampsia \[[@R9]\]. However, it is doubtful that cystatin C will be useful in monitoring renal function in pregnancy.

In contrast to cystatin C, very little is known about NGAL and the female reproductive tract. NGAL has been found in amniotic fluid, cervical mucus, and *coloster* \[[@R10]\]. However, the function of NGAL was not revealed in this study. Lavery *et al.* \[[@R11]\] found that urine NGAL was easily obtained in premature infants and that it correlated significantly with both birth weight and gestational age.

Neutrophil gelatinase-associated lipocalin belongs to the lipocalin family of proteins; NGAL was originally isolated from the supernatant of activated human neutrophils, but it is also expressed at a low level in other human tissues including the kidney \[[@R12]\]. Neutrophil gelatinase-associated lipocalin is synthesized systemically in response to kidney damage followed by glomerular filtration and tubular uptake; it could also be produced locally by injured tubules. In our study with pregnant women, both cystatin C and NGAL correlated with markers of inflammation better than with eGFR; they did not even show a significant correlation with serum creatinine. In a very recent paper, D'Anna *et al*. \[13\] reported that NGAL serum concentrations in the pre-eclampsia group were higher than in the control group, with significant differences in each trimester. They studied only 30 females in each group, and did not study in detail kidney function and other parameters.

The strength of our study is simultaneous measurement of serum NGAL and cystatin C. However, there are also some limitations. This is a single-centre, cross-sectional study, without measurement of GFR. It was not possible to study true GFR using either isotopic methods or insulin clearance; therefore we estimated GFR from known formulae. Similarly to cystatin C, although reference ranges have been reported, there is no current standard for serum NGAL measurements. In addition, testing for NGAL is only available in a limited number of laboratories using ELISA assay. However, urinary and plasma assay enabling more rapid measurement are under development.

In conclusion, serum NGAL in pregnancy might reflect subclinical inflammation rather than kidney function. It seems that NGAL, similarly to cystatin C, is not useful to monitor renal function in pregnancy.
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###### 

Basal clinical and biochemical characteristics of the studied groups

                                           Healthy volunteers *n* = 30   1^st^ trimester *n* = 46                       2^nd^ trimester *n* = 21                           3^rd^ trimester *n* = 63
  ---------------------------------------- ----------------------------- ---------------------------------------------- -------------------------------------------------- --------------------------------------------------
  **Age \[years\]**                        29.8 ±8.4                     26.7 ±5.2                                      26.2 ±5.8                                          26.6 ±5.5
  **Number of pregnancies**                1.5 ±0.9                      3.2 ±1.8                                       1.8 ±1.6                                           1.7 ±0.9
  **Ht \[%\]**                             39.87 ±2.48                   35.37 ±3.45[\*](#TF2){ref-type="table-fn"}     33.39 ±2.19[\*\*\*](#TF4){ref-type="table-fn"}     33.12 ±3.71[\*\*\*](#TF4){ref-type="table-fn"}
  **Hb \[g/dl\]**                          13.87 ±0.94                   12.59 ±1.38                                    12.13 ±1.19[\*](#TF2){ref-type="table-fn"}         11.06 ±1.41[\*\*\*](#TF4){ref-type="table-fn"}
  **Erythrocyte count \[× 10^12^/l\]**     4.24 ±0.29                    4.02 ±0.36[\*](#TF2){ref-type="table-fn"}      3.75 ±0.34[\*\*\*](#TF4){ref-type="table-fn"}      3.69 ±0.35[\*\*\*](#TF4){ref-type="table-fn"}
  **Leukocyte count \[× 10^12^/l\]**       5.53 ±1.61                    7.96 ±1.88[\*](#TF2){ref-type="table-fn"}      10.26 ±2.52[\*\*\*](#TF4){ref-type="table-fn"}     9.85 ±2.32[\*\*\*](#TF4){ref-type="table-fn"}
  **Neutrophil count \[× 10^12^/l\]**      4.87 ±3.87                    5.56 ±1.79                                     6.98 ±2.14[\*\*\*](#TF4){ref-type="table-fn"}      7.32 ±2.38[\*\*\*](#TF4){ref-type="table-fn"}
  **Platelet count \[× 10^9^/l\]**         241.45 ±44.55                 239.32 ±61.01                                  240.45 ±51.45                                      210.24 ±47.91
  **NGAL \[ng/ml\]**                       18.34 ±4.65                   19.96 ±24.16                                   38.85 ±25.08[\*](#TF2){ref-type="table-fn"}        24.03 ±21.52
  **Cystatin C \[mg/l\]**                  0.82 ±0.18                    0.81 ±0.19                                     0.86 ±0.22                                         1.24 ±0.37[\*\*](#TF3){ref-type="table-fn"}
  **MDRD equation \[ml/min\]**             99.78 ±14.42                  116.88 ±17.6[\*](#TF2){ref-type="table-fn"}    164.68 ±54.1[\*\*\*](#TF4){ref-type="table-fn"}    132.77 ±28.43[\*\*\*](#TF4){ref-type="table-fn"}
  **Cockcroft-Gault formula \[ml/min\]**   98.76 ±18.76                  128.72 ±22.98[\*](#TF2){ref-type="table-fn"}   182.75 ±56.54[\*\*\*](#TF4){ref-type="table-fn"}   172.05 ±39.22[\*\*\*](#TF4){ref-type="table-fn"}
  **CKD-EPI formula \[ml/min\]**           101.03 ±13.32                 118.68 ±11.29[\*](#TF2){ref-type="table-fn"}   133.24 ±11.78[\*\*\*](#TF4){ref-type="table-fn"}   123.22 ±14.58[\*\*\*](#TF4){ref-type="table-fn"}
  **Creatinine \[mg/dl\]**                 0.77 ±0.14                    0.66 ±0.09[\*](#TF2){ref-type="table-fn"}      0.51 ±0.11[\*](#TF2){ref-type="table-fn"}          0.61 ±0.13[\*](#TF2){ref-type="table-fn"}
  **hsIL 6 \[pg/ml\]**                     2.26 ±2.02                    5.61 ±2.85[\*\*](#TF3){ref-type="table-fn"}    6.95 ±3.62[\*\*\*](#TF4){ref-type="table-fn"}      7.52 ±4.16[\*\*\*](#TF4){ref-type="table-fn"}
  **hs-CRP \[mg/ml\]**                     1.74 ±0.52                    2.71 ±1.88                                     4.21 ±2.54[\*\*](#TF3){ref-type="table-fn"}        6.19 ±3.56[\*\*\*](#TF4){ref-type="table-fn"}
  **Iron \[µg/dl\]**                       110.56 ±25.76                 97.35 ±32.15                                   92.09 ±44.59                                       87.17 ±41.37[\*](#TF2){ref-type="table-fn"}
  **TIBC \[µg/dl\]**                       328.98 ±84.31                 359.12 ±77.58                                  323.81 ±70.84                                      514.99 ±87.62[\*](#TF2){ref-type="table-fn"}
  **Ferritin \[ng/dl\]**                   30.22 ±17.43                  27.63 ±19.52                                   38.31 ±34.68                                       28.66 ±27.82

*Values given are means ± SD,*

*p \< 0.05,*

*p \< 0.01,*

*p \< 0.001 vs. control group*
